Meningococcal surveillance in Southeast Asia and the Pacific
Helen S Marshall A B CA Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia
B University Department of Paediatrics, Women’s and Children’s Health Network, North Adelaide, SA, Australia
C Tel.: +61 8 8161 8115; Fax: +61 8 8161 7031; Email: helen.marshall@adelaide.edu.au
Microbiology Australia 42(4) 178-181 https://doi.org/10.1071/MA21050
Submitted: 18 August 2021 Accepted: 27 September 2021 Published: 4 November 2021
Journal Compilation © The Authors 2021 Open Access CC BY-NC-ND, published (by CSIRO Publishing) on behalf of the ASM
Abstract
Meningococcal disease is an uncommon infection associated with high case fatality rates, especially in some low resource countries. The burden of meningococcal disease in the Asia Pacific region is relatively low although likely to be underreported. Carriage rates of the causative bacteria, Neisseria meningitidis are also lower than in many other countries, with those of Asian ethnicity having a lower carriage prevalence than other ethnicities. There is a large degree of variability in establishment of infectious disease surveillance and case definitions used across Southeast Asia and Pacific nations. Although disease surveillance is a critically important component of disease control, not all countries mandate reporting of meningococcal disease and many do not have molecular typing capability. Adequate surveillance must include serogroup distribution and disease burden estimation. Improving surveillance capability and transfer to a more active surveillance model with capacity for PCR and genome sequencing will be important for early detection of outbreaks in the future.
References
[1] Casadevall, A. and Pirofski, L.A. (2000) Host-pathogen interactions: basic concepts of microbial commensalism, colonization, infection and disease. Infect. Immun. 68, 6511–6518.| Host-pathogen interactions: basic concepts of microbial commensalism, colonization, infection and disease.Crossref | GoogleScholarGoogle Scholar | 11083759PubMed |
[2] Marshall, H.S. et al. (2020) Meningococcal B vaccine and meningococcal carriage in adolescents, Australia. N. Engl. J. Med. 382, 318–327.
| Meningococcal B vaccine and meningococcal carriage in adolescents, Australia.Crossref | GoogleScholarGoogle Scholar | 31971677PubMed |
[3] Peterson, M.E. et al. (2019) Meningococcal serogroups and surveillance: a systematic review and survey. J. Glob. Health 9, .
| Meningococcal serogroups and surveillance: a systematic review and survey.Crossref | GoogleScholarGoogle Scholar | 30603079PubMed |
[4] Wang, B. et al. (2019) Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine 37, 2768–2782.
| Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar | 30987851PubMed |
[5] Marshall, H.S. et al. (2020) First state-wide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia. Med. J. Aust. 212, 89–93.
| First state-wide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia.Crossref | GoogleScholarGoogle Scholar | 31909501PubMed |
[6] Wang, B. et al. (2014) The clinical burden and predictors of sequelae following invasive meningococcal disease in Australian children. Pediatr. Infect. Dis. J. 33, 316–318.
| The clinical burden and predictors of sequelae following invasive meningococcal disease in Australian children.Crossref | GoogleScholarGoogle Scholar | 24030352PubMed |
[7] Kim, S.A. et al. (2012) An expanded age range for meningococcal meningitis: molecular diagnostic evidence from population-based surveillance in Asia. BMC Infect. Dis. 12, 310.
| 23164061PubMed |
[8] Vyse, A. et al. (2011) Meningococcal disease in Asia: an under-recognized public health burden. Epidemiol. Infect. 139, 967–985.
| Meningococcal disease in Asia: an under-recognized public health burden.Crossref | GoogleScholarGoogle Scholar | 21492496PubMed |
[9] Aye, A.M.M. et al. (2020) Meningococcal disease surveillance in the Asia–Pacific region (2020): the global meningococcal initiative. J. Infect. 81, 698–711.
| Meningococcal disease surveillance in the Asia–Pacific region (2020): the global meningococcal initiative.Crossref | GoogleScholarGoogle Scholar |
[10] (2019) Australia’s notifiable diseases status, 2015: annual report of the National Notifiable Diseases Surveillance System (NNDSS). Commun. Dis. Intell. 43, 1–186.
[11] Thangarajah, D. et al. (2020) Genomic characterization of recent and historic meningococcal serogroup E invasive disease in Australia: a case series. Clin. Infect. Dis. 70, 1761–1763.
| Genomic characterization of recent and historic meningococcal serogroup E invasive disease in Australia: a case series.Crossref | GoogleScholarGoogle Scholar | 31420664PubMed |
[12] Public Health Surveillance NZ (2019) Invasive Meningococcal Disease Report, January–December 2019. https://surv.esr.cri.nz/PDF_surveillance/MeningococcalDisease/2019/MeningococcalDisease_Q4_2019.pdf (accessed 13 August 2021).
[13] Singapore Ministry of Health (2018) Communicable Diseases Surveillance in Singapore 2017. https://www.moh.gov.sg/docs/librariesprovider5/default-document-library/air-droplet-borne-diseases-201724e7110f41a146509940275f6c3f7251.pdf
[14] Lahra, M.M. and Hogan, T.R. (2018) Australian Meningococcal Surveillance Programme annual report, 2019. Commun. Dis. Intell. 2020, 44.
[15] Parikh, S.R. et al. (2020) The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J. Infect. 81, 483–498.
| The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination.Crossref | GoogleScholarGoogle Scholar | 32504737PubMed |
[16] Martin, N.V. et al. (2016) Communicable Disease Network Australia Men WWG. Rise in invasive serogroup W meningococcal disease in Australia 2013–2015. Commun. Dis. Intell. Q. Rep. 40, E454–E459.
| 28043219PubMed |
[17] Brotherton, J. et al. (2004) Vaccine preventable diseases and vaccination coverage in Australia 2001 to 2002. Commun. Dis. Intell. Q. Rep. 28, S116.
[18] Sudbury, E.L. et al. (2020) Case manifestations and public health response for outbreak of meningococcal W disease, Central Australia, 2017. Emerg. Infect. Dis. 26, 1355–1363.
| Case manifestations and public health response for outbreak of meningococcal W disease, Central Australia, 2017.Crossref | GoogleScholarGoogle Scholar | 32568047PubMed |
[19] National Notifiable Disease Surveillance System, The Department of Health, Australian Government. https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-pub-datasets.htm (accessed 16 August 2021).
[20] Lahra, M.M. and Hogan, T.R. (2018) Australian Meningococcal Surveillance Programme annual report, 2019. Commun. Dis. Intell. 2020, 44.
[21] Marshall, H. et al. (2021) 4CMenB vaccine impact and effectiveness against meningococcal disease and gonorrhoea in a world first infant, child and adolescent program in South Australia. European Society of Paediatric Infectious Diseases Annual conference. 24–28 May 2021, Geneva, Switzerland.
[22] Petousis-Harris, H. et al. (2017) Effectiveness of a group B outer membrane vesicle vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet 390, 1603–1610.
| Effectiveness of a group B outer membrane vesicle vaccine against gonorrhoea in New Zealand: a retrospective case-control study.Crossref | GoogleScholarGoogle Scholar | 28705462PubMed |
[23] Dyet, K. et al. (2005) New Zealand’s epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery. Vaccine 23, 2228–2230.
| New Zealand’s epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery.Crossref | GoogleScholarGoogle Scholar | 15755601PubMed |
[24] Thailand Department of Disease Control (2020) https://ddc.moph.go.th/ (accessed 13 August 2021).
